- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Use of Molecular Tests That Assess Risk of Recurrence
In the first segment of this one-on-one interview series, John L. Fox, MD, MHA, senior medical director and associate vice president of medical affairs at Priority Health, discusses the use of molecular tests that assess the risk of cancer recurrence.
Several currently available molecular tests predict the risk of recurrence in early-stage breast cancer. Peter Salgo, MD, asks Dr Fox whether there is an advantage to a decentralized test versus a centralized test. Dr Fox explains that although decentralized tests offer more rapid turnaround times, there is no advantage to the patient or the payer, as patients do not begin treatment immediately. If 2 tests, 1 decentralized and 1 centralized, are equally beneficial and comparably priced, Dr Fox comments, he is indifferent as to which is utilized.
Dr Fox notes that professionals currently rely on the accuracy and transparency of information provided by the manufacturer of a test. He is hopeful, however, that more stringent evaluations of laboratory-developed tests and FDA oversight of companion diagnostics will help ensure the clinical and analytic validity of approved tests.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
